Mitchell 1997.

Study characteristics
Methods	Placebo‐controlled, industry‐funded, multicenter trial
Participants	Children; mixed tumors; ANC < 0.5 x 109/L
Interventions	G‐CSF (filgrastim) 5 mcg/kg IV ATB: Gentamicin plus Piperacilin plus Flucloxacilin OR Gentamicin plus Imipenen‐Cilastatin
Outcomes	Overall mortality People with hospitalization for greater than 10 days Time to neutrophil recovery
Notes	Hospital discharge criteria: afebrile for at least 72 hours; ANC at least 200/mm3 Duration of grade IV neutropenia reported as days to absolute granulocyte recovery to > 0.5 x 109/L
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Description of method of sequence generation not provided
Allocation concealment (selection bias)	Low risk	The study drug and placebo were delivered to the ward in identically labeled syringes, and the staff and investigators were unaware of treatment allocation until the study had been completed.
Blinding (performance bias and detection bias) All outcomes	Low risk	Double blinding was employed
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Staff and investigators were unaware of treatment allocation until the study had been completed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	We were not able to assess the outcomes for which blinding was employed based on the information provided in the article
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis used, withdrawals are described
Other bias	Low risk	Prespecified values of sample size, alpha and beta errors were provided